{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T19:03:30Z","timestamp":1770577410720,"version":"3.49.0"},"reference-count":43,"publisher":"Informa UK Limited","issue":"1","funder":[{"name":"Genentech"},{"name":"AstraZeneca"},{"name":"Merck"},{"DOI":"10.13039\/100018201","name":"Syndax","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018201","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ventana-Roche"},{"DOI":"10.13039\/100006640","name":"Open Society Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006640","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.2217\/1750743x.1.1.19","type":"journal-article","created":{"date-parts":[[2010,3,10]],"date-time":"2010-03-10T12:38:26Z","timestamp":1268224706000},"page":"19-25","source":"Crossref","is-referenced-by-count":62,"title":["MAGE A3 Antigen-Specific Cancer Immunotherapeutic"],"prefix":"10.1080","volume":"1","author":[{"given":"Nir","family":"Peled","sequence":"first","affiliation":[{"name":"University of Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana B","family":"Oton","sequence":"additional","affiliation":[{"name":"University of Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred R","family":"Hirsch","sequence":"additional","affiliation":[{"name":"University of Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2008,12,22]]},"reference":[{"key":"e_1_3_2_2_1_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-991"},{"key":"e_1_3_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-999"},{"key":"e_1_3_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03954"},{"key":"e_1_3_2_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2005.05.001"},{"key":"e_1_3_2_2_5_1","first-page":"CD001425","article-title":"Immunotherapy for advanced renal cell cancer.","author":"Coppin C","year":"2005","unstructured":"Coppin C , PorzsoltF, AwaA, KumpfJ, ColdmanA, WiltT: Immunotherapy for advanced renal cell cancer.Cochrane Database Syst. Rev.CD001425 (2005).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_2_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.044"},{"key":"e_1_3_2_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07422-4"},{"key":"e_1_3_2_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2003.09.015"},{"key":"e_1_3_2_2_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_3_2_2_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm474"},{"key":"e_1_3_2_2_11_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2008.s.002"},{"key":"e_1_3_2_2_12_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.6.1526"},{"key":"e_1_3_2_2_13_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.565"},{"key":"e_1_3_2_2_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.4.6.937"},{"key":"e_1_3_2_2_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/08830180600992407"},{"key":"e_1_3_2_2_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910520528"},{"key":"e_1_3_2_2_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910630313"},{"key":"e_1_3_2_2_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01246677"},{"key":"e_1_3_2_2_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910560612"},{"key":"e_1_3_2_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(95)80053-0"},{"key":"e_1_3_2_2_21_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.11.6716"},{"key":"e_1_3_2_2_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000091185"},{"key":"e_1_3_2_2_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2585"},{"issue":"10","key":"e_1_3_2_2_24_1","first-page":"4072","article-title":"A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry.","volume":"61","author":"Pascolo S","year":"2001","unstructured":"Pascolo S , SchirleM, GuckelB et al.: A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry.Cancer Res.61(10) , 4072\u20134077 (2001).","journal-title":"Cancer Res."},{"issue":"3","key":"e_1_3_2_2_25_1","first-page":"947","article-title":"MAGE-6 encodes HLA-DR\u03b21*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.","volume":"9","author":"Tatsumi T","year":"2003","unstructured":"Tatsumi T , KiersteadLS, RanieriE et al.: MAGE-6 encodes HLA-DR\u03b21*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.Clin. Cancer Res.9(3) , 947\u2013954 (2003).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"e_1_3_2_2_26_1","first-page":"509","article-title":"Frequent cytolytic T-cell responses to peptide MAGE-A10(254\u2013262) in melanoma.","volume":"61","author":"Valmori D","year":"2001","unstructured":"Valmori D , DutoitV, Rubio-GodoyV et al.: Frequent cytolytic T-cell responses to peptide MAGE-A10(254\u2013262) in melanoma.Cancer Res.61(2) , 509\u2013512 (2001).","journal-title":"Cancer Res."},{"key":"e_1_3_2_2_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0230-y"},{"key":"e_1_3_2_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(95)80053-0"},{"key":"e_1_3_2_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.06.038"},{"key":"e_1_3_2_2_30_1","first-page":"1156","article-title":"Genes encoding tumor-specific antigens are expressed in human myeloma cells.","volume":"94","author":"Van Baren N","year":"1999","unstructured":"Van Baren N , BrasseurF, GodelaineD et al.: Genes encoding tumor-specific antigens are expressed in human myeloma cells.Blood94 , 1156\u20131164 (1999).","journal-title":"Blood"},{"key":"e_1_3_2_2_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1203"},{"issue":"1","key":"e_1_3_2_2_32_1","first-page":"140","article-title":"Cancer vaccines, a critical review \u2013 part I.","volume":"3","author":"Mitchell MS","year":"2002","unstructured":"Mitchell MS : Cancer vaccines, a critical review \u2013 part I.Curr. Opin. Invest. Drugs3(1) , 140\u2013149 (2002).","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"e_1_3_2_2_33_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.3289"},{"key":"e_1_3_2_2_34_1","unstructured":"Kensil CR SoltysikS PatelU et al.: Vaccines. Channock RM Ginsburg HS Brown F et al.: (Eds). Cold Spring Harbor Laboratory Press Cold Spring Harbor NY USA 36\u201340 (1992)."},{"key":"e_1_3_2_2_35_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.3289"},{"key":"e_1_3_2_2_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0707140104"},{"key":"e_1_3_2_2_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21264"},{"key":"e_1_3_2_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00479-3"},{"key":"e_1_3_2_2_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200403000-00006"},{"key":"e_1_3_2_2_40_1","first-page":"7554","article-title":"Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE A3 immunotherapeutic as adjuvant therapy in stage IB\/II non-small cell lung cancer (NSCLC).","volume":"25","author":"Vansteenkiste J","year":"2007","unstructured":"Vansteenkiste J , ZielinskiM, LinderA et al.: Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE A3 immunotherapeutic as adjuvant therapy in stage IB\/II non-small cell lung cancer (NSCLC).ASCO Meeting Abstracts25 , 7554 (2007).","journal-title":"ASCO Meeting Abstracts"},{"key":"e_1_3_2_2_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.9065"},{"key":"e_1_3_2_2_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318174e9a7"},{"key":"e_1_3_2_2_43_1","doi-asserted-by":"crossref","first-page":"B1","DOI":"10.1097\/01.JTO.0000283139.22682.5e","article-title":"A multicentre Phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis.","volume":"2","author":"Butts CM","year":"2007","unstructured":"Butts CM , MaksymiukA, GossG et al.: A multicentre Phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis.J. Thorac Oncol.S2 , B1\u201301 (2007).","journal-title":"J. Thorac Oncol."}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/1750743X.1.1.19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T19:43:05Z","timestamp":1715974985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/1750743X.1.1.19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,22]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.2217\/1750743X.1.1.19"],"URL":"https:\/\/doi.org\/10.2217\/1750743x.1.1.19","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,22]]}}}